NCT04479644View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 13, 2020

Primary Completion Date

February 3, 2021

Study Completion Date

February 3, 2021

Conditions
COVID-19
Interventions
DRUG

BRII-198

BRII-198 given intravenously

DRUG

Placebo

Placebo given intravenously

Trial Locations (1)

Unknown

Investigative Site, Beijing

Sponsors
All Listed Sponsors
collaborator

TSB Therapeutics (Beijing) CO.LTD

INDUSTRY

lead

Brii Biosciences Limited

INDUSTRY

NCT04479644 - Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198 | Biotech Hunter | Biotech Hunter